PERSPECTA

News from every angle

← Back to headlines

EyePoint Shares Plunge as DURAVYU Misses Primary Endpoint

EyePoint shares experienced a significant drop after its drug DURAVYU failed to meet its primary endpoint in a clinical trial.

17 Aug, 14:20 — 17 Aug, 14:20
PostShare

Sources

Showing 1 of 1 sources
investing-com1d ago

EyePoint shares plunge as DURAVYU misses primary endpoint By Investing.com - Investing.com South Africa

EyePoint shares plunge as DURAVYU misses primary endpoint By Investing.com  Investing.com South Africa

Read full article →

Related Stories

Farmers Accuse Officials of Failing to Address Drought Severity

16m ago

US Pending Home Sales Plunge to Near Record Lows in July

42m ago

Pakistan Government Hikes Petrol and Diesel Prices

43m ago

Climate Catastrophes in Europe Cost Billions, Burdening Citizens

47m ago